Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Denali Therapeutics (DNLI) Return on Equity (2018 - 2026)

Denali Therapeutics has reported Return on Equity over the past 8 years, most recently at 0.01% for Q4 2025.

  • Quarterly Return on Equity changed 0.0% to 0.01% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.01% through Dec 2025, changed 0.0% year-over-year, with the annual reading at 0.0% for FY2025, 0.0% changed from the prior year.
  • Return on Equity was 0.01% for Q4 2025 at Denali Therapeutics, down from 0.01% in the prior quarter.
  • Over five years, Return on Equity peaked at 0.0% in Q2 2021 and troughed at 0.01% in Q4 2025.
  • The 5-year median for Return on Equity is 0.0% (2024), against an average of 0.0%.
  • The largest YoY upside for Return on Equity was 1bps in 2021 against a maximum downside of 0bps in 2021.
  • A 5-year view of Return on Equity shows it stood at 0.0% in 2021, then fell by -20bps to 0.0% in 2022, then soared by 62bps to 0.0% in 2023, then tumbled by -146bps to 0.0% in 2024, then crashed by -59bps to 0.01% in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Return on Equity are 0.01% (Q4 2025), 0.01% (Q3 2025), and 0.0% (Q2 2025).